首页> 外文期刊>Clinical advances in hematology & oncology: H&O >LUNG CANCER IN FOCUS: Moving Beyond Monotherapy in the Immunotherapeutic Arena: Prospects for Combination Therapies in Lung Cancer
【24h】

LUNG CANCER IN FOCUS: Moving Beyond Monotherapy in the Immunotherapeutic Arena: Prospects for Combination Therapies in Lung Cancer

机译:肺癌焦点:在免疫治疗竞技场中超越单疗法:肺癌联合疗法的前景

获取原文
获取原文并翻译 | 示例
           

摘要

H&O Why would patients with lung cancer benefit from a new treatment modality beyond surgery, chemotherapy, and radiation? SA Treatment of lung cancer depends on the stage. Patients with early-stage lung cancer, known as stage 1, still have a very good chance of being cured with surgery alone. Chemotherapy and surgery can potentially cure patients with stage 2 disease. Patients with stage 3 disease can be cured by chemotherapy and radiation, with or without surgery. These modalities are still the standard of care and are associated with a good chance of cure.
机译:H&O为什么肺癌的患者会受益于外科,化疗和辐射的新治疗方式? SA治疗肺癌取决于舞台。 患有早期肺癌的患者,称为第1阶段,仍然有很好的机会单独用手术治愈。 化疗和手术可以治愈2阶段疾病的患者。 患有3阶段疾病的患者可以通过化疗和辐射治愈,有或没有手术。 这些方式仍然是护理标准,与良好的治愈机会有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号